ArticleJournal of ovarian research2026
Patient-reported outcomes after long-term period of niraparib maintenance in platinum-sensitive recurrent ovarian cancer: a prospective, multicenter cohort study.
Article in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundConsidering high frequency of recurrence and usage of poly (ADP-ribose) polymerase inhibitor (PARPi) maintenance, long-term usage of PARPi certainly has been a trend for relapsed ovarian cancer. However, the quality of life (QOL) and symptom control in these patients still remains to be clarified, especially after a long-term period of PARPi maintenance. Herein, we collected the patient-reported outcomes (PROs) in platinum-sensitive recurrent ovarian cancer (PSROC) receiving niraparib, a highly selective PARPi, as maintenance therapy after approximately 3 years.
methodsThis study enrolled 604 patients screened from 3154 PSROC all over the country. PROs data were collected at 1, 2 and 3 months after enrollment based on questionnaires, including the European QOL Scale five-dimension five-level (EQ-5D-5 L), the European QOL-visual analogue scale (EQ-VAS) and the Functional Assessment of Cancer Therapy–Ovarian Symptoms Index (FOSI).
resultsThe median period of niraparib maintenance was 34.8 months (range: 30.5–46.7 months) in 604 PSROC. Stage III-IV, BRCA mutation were found in 54.6% (n = 330) and 23.4% (n = 104) ( of patients before recurrence, respectively. For PROs data, QOL and symptom control remained stable and considerable throughout follow-up. The least square mean (LS mean) of EQ-5D-5L health utility index (HUI), EQ-VAS and FOSI were 0.974 (SE 0.001), 83.7 (SE 0.248) and 30.8 (SE 0.033), respectively. LS mean change of EQ-5D-5 L HUI, EQ-VAS and FOSI from baseline to the final timepoint were − 0.004 (SE 0.001), -0.609 (SE 0.248) and − 0.359 (SE 0.033), respectively. Subgroup analysis indicated no significant difference in EQ-5D-5 L HUI, EQ-VAS and FOSI scores between BRCA mutation group and BRCA wildtype group (p > 0.05 at three timepoints), with PROs data similar to the whole 604 PSROC in both subgroups.
conclusionsPRO-based surveillance showed satisfactory QOL and stable symptom control in PSROC after long-term period of niraparib maintenance, regardless of BRCA status. This real-world research highlights the significance of long-term usage of niraparib and PROs in PSROC management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.